Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -56.34% | -55.47% | -9.86% | 37.97% | 51.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -56.34% | -55.47% | -9.86% | 37.97% | 51.86% |
| Cost of Revenue | -43.08% | 89.11% | -12.11% | 38.39% | 36.80% |
| Gross Profit | -67.85% | -113.74% | -8.63% | 37.96% | 67.90% |
| SG&A Expenses | -2.64% | 71.00% | 64.72% | 33.50% | 23.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.11% | 73.10% | 54.59% | 33.99% | 25.05% |
| Operating Income | -8.40% | -160.42% | -92.69% | -32.35% | -18.46% |
| Income Before Tax | 67.28% | -111.56% | -100.81% | 200.68% | -229.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 67.28% | -111.56% | -100.81% | 200.68% | -229.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.28% | -111.56% | -100.81% | 200.68% | -229.09% |
| EBIT | -8.40% | -160.42% | -92.69% | -32.35% | -18.46% |
| EBITDA | -8.34% | -161.75% | -93.17% | -32.08% | -18.51% |
| EPS Basic | 50.00% | -- | -- | -- | -100.00% |
| Normalized Basic EPS | 100.00% | -- | -- | -- | -- |
| EPS Diluted | 50.00% | -- | -- | -- | -100.00% |
| Normalized Diluted EPS | 100.00% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 4.35% | 1.81% | 2.08% | 1.12% | 0.44% |
| Average Diluted Shares Outstanding | 4.35% | 1.81% | 2.08% | 392.72% | 0.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |